Cellular ADMA: regulation and action.

@article{Teerlink2009CellularAR,
  title={Cellular ADMA: regulation and action.},
  author={T. Teerlink and Z. Luo and F. Palm and C. Wilcox},
  journal={Pharmacological research},
  year={2009},
  volume={60 6},
  pages={
          448-60
        }
}
Asymmetric (N(G),N(G)) dimethylarginine (ADMA) is present in plasma and cells. It can inhibit nitric oxide synthase (NOS) that generates nitric oxide (NO) and cationic amino acid transporters (CATs) that supply intracellular NOS with its substrate, l-arginine, from the plasma. Therefore, ADMA and its transport mechanisms are strategically placed to regulate endothelial function. This could have considerable clinical impact since endothelial dysfunction has been detected at the origin of… Expand
Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets?
Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect or Association?
Role of asymmetrical dimethylarginine in the progression of renal disease
ADMA, homocysteine and redox status improvement affected by 7-nitroindazole in spontaneously hypertensive rats.
Nitric oxide synthase derangements and hypertension in kidney disease
  • C. Baylis
  • Medicine
  • Current opinion in nephrology and hypertension
  • 2012
Measurement of Arginine Metabolites: Regulators of Nitric Oxide Metabolism
Restoration of Asymmetric Dimethylarginine–Nitric Oxide Balance to Prevent the Development of Hypertension
Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 161 REFERENCES
Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension.
Nitric oxide deficiency in chronic kidney disease.
  • C. Baylis
  • Biology, Medicine
  • American journal of physiology. Renal physiology
  • 2008
L-arginine transporters in cardiovascular disease: a novel therapeutic target.
...
1
2
3
4
5
...